Trials / Completed
CompletedNCT02671214
The Effect of Selected Fibres and Flours in Flat Bread on Post-prandial Blood Glucose Responses
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Unilever R&D · Industry
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Identify one or more flat bread mixes that produce a reduction in positive incremental area under the curve (iAUC) of post-prandial glucose relative to the control product.
Detailed description
This study was a double-blind, randomised, balanced incomplete block design exploratory study of efficacy, with 11 active treatments compared to a control product in 42 healthy subjects to see if a mix of active ingredients (viscous fibres and flours) lowered the post-prandial glucose (PPG) response in capillary blood (finger prick) over a two and three hours period, relative to the control product. Every subject received the control and 4 out of the 11 treatments on five separate test days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Control | 100 g high fibre flour |
| OTHER | Active 2 | 98 g high fibre flour + 2 g guar gum |
| OTHER | Active 3 | 88 g high fibre flour + 2 g guar gum + 10 g legume flour |
| OTHER | Active 4 | 83 g high fibre flour + 2 g guar gum + 15 g legume flour |
| OTHER | Active 5 | 96 g high fibre flour + 4 g guar gum |
| OTHER | Active 6 | 86 g high fibre flour + 4 g guar gum + 10 g legume flour |
| OTHER | Active 7 | 81 g high fibre flour + 4 g guar gum + 15 g legume flour |
| OTHER | Active 8 | 94 g high fibre flour + 6 g guar gum |
| OTHER | Active 9 | 98 g high fibre flour + 2 g konjac mannan |
| OTHER | Active 10 | 96 g high fibre flour + 4 g konjac mannan |
| OTHER | Active 11 | 100 g low fibre flour |
| OTHER | Active 1 | 85 g high fibre flour + 15 g legume flour |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2016-02-02
- Last updated
- 2016-02-02
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02671214. Inclusion in this directory is not an endorsement.